CoChat

Cyclophilin A release as a biomarker of necrotic cell death

Open access
Christofferson, D E, Yuan, J · 2010 · Cell Death & Differentiation
Cited by 83

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Necroptosis is a form of programmed necrotic cell death mediated by the activity of receptor-interacting protein 1 (RIP1) kinase (1). This type of cell death is caspase-independent and marked by early membrane permeabilization and does not exhibit any other hallmarks of apoptotic cell death such as phosphatidylserine externalization or DNA strand breaks (1). Thus, the markers available to characterize apoptotic cell death cannot be used to analyze necroptosis. Only one marker of necrosis has been identified, and that is the release of the chromatin protein high mobility group B1 (HMGB1) (2). However, we have found the release of HMGB1 to occur at a late stage of death. In this study we have found that cyclophilin A (CypA), a cytosolic peptidyl-prolyl cis-trans isomerase, is released early in necroptosis. We propose that the release of CypA may be used as a biomarker for necroptosis and other cell death processes when the integrity of the plasma membrane is compromised. Since necroptotic cells exhibit early permeabilization of the plasma membrane (1), we hypothesized that the release of intracellular protein(s) may be used as a biomarker for necroptosis. Treatment of L929 cells with zVAD.fmk induces necroptosis, which can be inhibited by treatment with the RIP1 kinase inhibitor, necrostatin-1 (Nec-1) (1). We observed the appearance of a strong band around 17 kD by SDS-PAGE in the supernatant of zVAD-treated L929 cells at an early stage of cell death (Supplemental Figure 1, top panel). Mass spectrometry analysis identified this band as cyclophilin A (CypA), a soluble cytosolic protein that catalyzes the cis-trans isomerization of proline bonds. The release of CypA was further confirmed by western blot (Supplemental Figure 1, bottom panel). In contrast to the necrosis marker HMGB1, the timing of CypA release precedes or occurs around the same time as that of HMGB1 (Figure 1A). Nec-1 blocks the release of CypA into the supernatant (Figure 1B). Figure 1 Cyclophilin A is released from necroptotic cells as a result of cytoplasmic membrane permeabilization. A, L929 cells were treated with 100μM zVAD.fmk for indicated hrs. The supernatants were collected, concentrated, and analyzed by SDS-PAGE followed ... To determine if the release of CypA from the cells was specific to necroptosis, we tested the supernatant of apoptotic cells. We were unable to detect CypA released from Jurkat cells treated with TNFα and CHX to induce apoptosis, even though intracellular CypA appears to be degraded at 24h when cell death was completed (Figure 1C). However, FADD-deficient Jurkat cells, which undergo necroptosis in response to TNFα, did release CypA (Figure 1C). We also tested different inducers of apoptosis for the ability to release CypA. Treatment of doxorubicin and staurosporine caused a small amount of CypA release at later stages of cell death, hours after caspase-3 activation (Supplemental Figures 2-3). Thus, CypA may also be released after permeabilization of the plasma membrane in late phase of apoptotic cell death. However, since apoptotic cells are efficiently engulfed in vivo, the release of CypA by apoptotic cells may not occur in vivo. To examine if CypA could be released by permeabilization of the cells, we treated cells with the detergent digitonin, which led to cell membrane permeabilization. We found that digitonin permeabilized cells also release CypA (Supplemental Figure 4). This may explain why CypA is released during necroptosis, which exhibit early permeabilization of the plasma membrane (1). Elevated serum CypA levels have been found in inflammatory diseases such as rheumatoid arthritis and CypA is secreted in vivo by progressive solid tumors (3, 4). CypA release from necrotic cells may play a role in the effects of necrosis on surrounding tissue. Necrosis is typically associated with inflammation. Necroptosis occurs in models of neuronal ischemia and traumatic brain injury (1, 5). Treatment with Nec-1 significantly reduces cell death and inhibits the recruitment of neutrophils to the injured area (5). Extracellular CypA has been shown to induce a rapid inflammatory response upon injection in vivo and to recruit neutrophils. This recruitment is dependent on the CypA receptor, CD147 (EMMPRIN) (3). Signaling of CypA through CD147 is proposed to contribute to the migration of neutrophils into the joints in rheumatoid arthritis and possibly in the destruction of bone and cartilage in the disease (6). We propose that CypA may be used as a biomarker for necroptosis. The release of CypA, in combination with Nec-1, a specific inhibitor of necroptosis, may be used as an assay for the activation of necroptosis, both in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2010.123

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Christofferson, D. E., & Yuan, J.
Venue
Cell Death & Differentiation
Published
2010-10-08
Volume
17
Issue
12
Pages
1942-1943
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2046025619
Cited by
83
References
1
FWCI
2.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.